



Denmark

Danish Medicines Agency (DKMA)

Major reforms from 2007 till now

- Agreement between the Ministry of Health and Prevention and the association of the Pharmaceutical Industry on price ceiling for 2007-2008, and continuation of the agreement for 2009-2011.
- The HPV vaccine is part of the Childrens Vaccination program. The program provides free vaccines for 12 year old girls. (January/2009)
- Higher patient co-payment in general to finance the HPV-vaccine. (May/2008)

Current and planned measures

- Reassessment of reimbursement status of antihypertensives (ATC groups C02, C03, C07, C08, C09). As of 13 July 2009 the more expensive ACE inhibitors will lose their reimbursement, and the more expensive calcium antagonists and all the angiotensin II antagonists will be eligible for conditional reimbursement. The decision to change the reimbursement is essentially based on the class effect combined with the price aspect.
- Reassessment of reimbursement status of medicinal products in ATC group A and J.

Current pharmaceutical pricing and reimbursement system (as of 2/2009)

Pricing

- Free pricing for all pharmaceuticals – no price negotiation or price approval etc. Price changes possible every two weeks. Notification to the DKMA.
- Wholesale mark ups are not publicly known
- Linear mark-up scheme for all pharmaceuticals restricted to sale from pharmacies.
- Standard VAT rate of 25 % for all pharmaceuticals

Reimbursement

- Positive list in place
- Reimbursement rates rises with rising consumption, “needs-based reimbursement system”, (0%, 50%, 75% and 85%)
- Reference price system in place.
- Percentage co-payments. Prescription fee of DKK 10 per package.